Pharming (PHAR) Capital Expenditures (2019 - 2025)
Pharming's (PHAR) quarterly Capital Expenditures came in at -$749000.0 in Q4 2025, up 5.19% YoY from -$712045.7 in Q4 2024, and up 5.19% on a QoQ basis from -$790000.0 in Q4 2024.
Pharming (PHAR) Capital Expenditures (2019 - 2025) Analysis & Trends
Pharming (PHAR) has 7 years of Capital Expenditures data on file, last reported at -$749000.0 in Q4 2025.
- Quarterly Capital Expenditures rose 5.19% year-over-year to -$749000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$3.3 million (down 21.97% YoY) and the FY2025 annual result came in at $749000.0, down 6.37% from the prior year.
- Capital Expenditures grew to -$749000.0 in Q4 2025, from -$790000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of -$147000.0 in Q3 2023 to a low of -$2.0 million in Q3 2021.
- A 5-year average of -$899994.0 and a median of -$769500.0 in 2024 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2021 — Capital Expenditures plunged 40148.79% — and 2022, when it jumped 89.37%.
- Tracing PHAR's Capital Expenditures over 5 years: stood at -$2.0 million in 2021, then jumped by 89.37% to -$208000.0 in 2022, then slumped by 590.87% to -$1.4 million in 2023, then surged by 45.02% to -$790000.0 in 2024, then increased by 5.19% to -$749000.0 in 2025.
- The last three Capital Expenditures figures came in at -$749000.0 (Q4 2025), -$790000.0 (Q4 2024), and -$366000.0 (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Pharming | 824.47 Mn | 666.19 Mn | 141.47 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -749,000.00 |
| Dec 31, 2025 | -749,000.00 |
| Dec 31, 2024 | -790,000.00 |
| Dec 31, 2024 | -790,000.00 |
| Sep 30, 2024 | -366,000.00 |
| Sep 30, 2024 | -366,000.00 |
| Dec 31, 2023 | -1.44 Mn |
| Dec 31, 2023 | -1.44 Mn |
| Sep 30, 2023 | -147,000.00 |
| Sep 30, 2023 | -147,000.00 |
| Jun 30, 2023 | -986,000.00 |
| Jun 30, 2023 | -986,000.00 |
| Dec 31, 2022 | -208,000.00 |
| Dec 31, 2022 | -208,000.00 |
| Sep 30, 2022 | -342,000.00 |
| Sep 30, 2022 | -342,000.00 |
| Dec 31, 2021 | -1.96 Mn |
| Dec 31, 2021 | -1.96 Mn |
| Sep 30, 2021 | -2.02 Mn |
| Sep 30, 2021 | -2.02 Mn |